List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Drug Profiles
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galunisertib monohydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFH-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3200882 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Antagonize TGF-beta for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06952229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKI-2162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK5 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRI-011381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0427736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vactosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-14618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-13027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Dormant Products
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2019: MedPacto passes tech assessment, seeks KOSDAQ listing this year
May 15, 2019: Eli Lilly presents update on phase Ib study of galunisertib at ASCO 2019
Jan 23, 2019: Study Suggests new strategy to treat advanced Prostate Cancer
Dec 21, 2018: MedPacto announce approval for the Vactosertib + Durvalumab Combination Trial Application
Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
May 18, 2016: Lilly to present data on TGF• small-molecule kinase inhibitor galunisertib at ASCO
May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013
Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting
Jul 01, 2009: Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecule Activin-Like Kinase 5 Inhibitor (ALK-5) From Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Allander Biotechnologies LLC, H2 2019
Pipeline by Auxagen Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by FBM Therapeutics LLC, H2 2019
Pipeline by GenFleet Therapeutics, H2 2019
Pipeline by MedPacto Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2019
Pipeline by SK Chemicals Co Ltd, H2 2019
Pipeline by Synthis LLC, H2 2019
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Pipeline by TherapyX Inc, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Pipeline by TiumBio Co Ltd, H2 2019
Pipeline by Yuhan Corp, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Allander Biotechnologies LLC
• Auxagen Inc
• Eli Lilly and Co
• FBM Therapeutics LLC
• GenFleet Therapeutics
• MedPacto Inc
• Pfizer Inc
• Shanghai Yingli Pharmaceutical Co Ltd
• SK Chemicals Co Ltd
• Synthis LLC
• Taisho Pharmaceutical Holdings Co Ltd
• TherapyX Inc
• Theravance Biopharma Inc
• TiumBio Co Ltd
• Yuhan Corp